Trial Profile

Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Gastric cancer; Large cell carcinoma; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Jul 2024 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Enrollment was stopped after 16 patients in the expansion cohort due to accrual delays and changes in standard treatment
07 Jun 2022 Results assessing safety and efficacy of avelumab with perioperative CRT in resectable esophageal and gastroesophageal junction cancer, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com